NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia

NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia

Chronic myeloid leukemia (CML) is a hematological malignancy characterized by the presence of t(9;22) chromosomal translocation that results in BCR-ABL fusion gene. ABL tyrosine kinase inhibitors (TKIs), such as imatinib, nilotinib, and dasatinib, are currently the front-line treatment options for C...

Full description

Bibliographic Details
Main Authors: Ming-Chin Chang, Hung-I Cheng, Kate Hsu, Yen-Ning Hsu, Chen-Wei Kao, Yi-Fang Chang, Ken-Hong Lim, Caleb Gonshen Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-01-01
Series:Frontiers in Immunology
Subjects:
CML
BCR-ABL
major molecular response (MMR)
deep molecular response (DMR)
natural killer cell
NKG2A
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2018.03152/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2018.03152/full

Similar Items